Five Directors at Dova Pharmaceuticals Inc sold after exercising options/sold 13,111 shares at between 27.900USD and 28.000USD. The significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades ...
Dova Pharmaceuticals to be Acquired by Swedish Orphan Biovitrum AB (Sobi) Consideration of up to $29.00 per share includes $27.50 per share in upfront cash and an additional $1.50 per share upon regulatory approval of DOPTELET® for chemotherapy-induced thrombocytopenia (CIT) as a Contingent Value Right (CVR) for a total potential consideration of up to $915 million on a fully diluted basisAcquisition of Dova expected to enhance Sobi’s position as a leader in hematology and orphan diseases and maximize the availability of DOPTELET to patients globally Transaction expected to be completed in ...
Dova Pharmaceuticals to Present at 2019 Cantor Global Healthcare Conference DURHAM, N.C., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Jason Hoitt, Chief Commercial Officer, will present a company overview at the 2019 Cantor Global Healthcare Conference on Wednesday, October 2, 2019 at 4:10 p.m. ET in New York, NY. A live audio webcast of the event will be available via the "Investor Relations" page of the Dova website, . Please log on through Dova's website approximately 10 minutes before the scheduled start time. A replay of the webc...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.